Fig. 4From: Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?Scenario analyses estimating the influence of different model assumptions on a) the ICER of the lifetime benefit-based treatment strategy of 10% of the patients vs. no treatment and b) the ICER of the 10-year risk-based treatment strategy of 10% of the patients vs no treatmentBack to article page